Table 2.

Revised TMNB classification for MF and SS.

Skin (T)
T1	Limited patches/plaques (covering <10% of the total skin surface)
T1a	Patches only
T1b	Plaques/papules ± patches
T2	Generalized patches/plaques (covering ≥10% of the total skin surface)
T2a	Patches only
T2b	Plaques/papules ± patches
T3	Tumor(s) ≥ 1cm diameter
T4	Confluence of erythema covering ≥80% of the body surface area
Lymph node (N)
N0	No clinically abnormal peripheral lymph nodes
N1	Clinically abnormal peripheral lymph nodes; dermatopathic lymphadenopathy or histopathological involvement by isolated atypical lymphocytes, without alteration of the lymph node architecture
N1a	Clone negative or equivocal
N1b	Clone positive and identical to skin
N2	Clinically abnormal peripheral lymph nodes; histopathological involvement by aggregates of atypical lymphocytes, without alteration of the lymph node architecture
N2a	Clone negative or equivocal
N2b	Clone positive and identical to skin
N3	Clinically abnormal peripheral lymph nodes; frank histopathological involvement and partial/complete effacement of the lymph node architecture
N3a	Clone negative or equivocal
N3b	Clone positive and identical to skin
Nx	Clinically abnormal peripheral lymph nodes; without histopathological confirmation
Viscera (M)
M0	Without visceral involvement
M1	With visceral involvement
M1a	Bone marrow involvement
M1b	Non-bone marrow visceral involvement
Blood (B)
B0	Absence of significant blood involvement (< 250/µL of CD4+CD26- or CD4+CD7- cells)
B0a	Clone negative or equivocal
B0b	Clone positive and identical to skin
B1	Low tumor burden in the blood, but do not fulfill B2 criteria
B1a	Clone negative or equivocal
B1b	Clone positive and identical to skin
B2	High tumor load in the blood (CD4/CD8 ≥ 10; CD4+CD7- ≥ 40%; CD4+CD26- ≥ 30%; ≥ 1000/µL of CD4+CD26- or CD4+CD7- cells or other aberrant population of lymphocytes identified by flow cytometry)
B2a	Clone negative or equivocal
B2b	Clone positive and identical to skin
Bx	Unable to quantify blood involvement